Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

(W)Initiative for womeN and GirlS affected by Female Genital Schistosomiasis

Project description

Tackling female genital schistosomiasis

Female genital schistosomiasis (FGS) represents an under-recognised public health issue, particularly in tropical regions. It is caused by the parasitic worm Schistosoma haematobium, which deposits eggs in the tissues of the female reproductive tract. This leads to chronic inflammation, pain, infertility and increased susceptibility to sexually transmitted infections. To improve care and access to treatment, the EU-funded WINGS-4-FGS project proposes to integrate FGS management into sexual and reproductive health services. The consortium will test anti-inflammatory drugs, implement self-sampling diagnostic methods and provide training to reduce associated stigma. Ultimately, these strategies will improve local healthcare capacity and contribute to more effective management and prevention of FGS.

Objective

WINGS-4-FGS addresses pressing needs for tackling Female Genital Schistosomiasis (FGS) in Africa, with the objective of improving case management and therapeutic access while integrating care into sexual and reproductive health strategies. FGS, a consequence of schistosomiasis caused by the parasite Schistosoma haematobium, affects millions of women and girls in sub-Saharan Africa, leading to significant morbidity and reproductive health issues. Current treatment barriers include limited knowledge, associated stigma, a lack of effective treatment, and inadequate diagnostic tools. WINGS-4-FGS proposes a multifaceted, holistic approach and aims to: i) investigate the efficacy of anti-inflammatory medications as add-ons to praziquantel; ii) implement training programs to increase awareness and medical care competency; iii) implement a community-based, two-step, self-sampling diagnostic strategy; iv) assess barriers and facilitators for integrating FGS into existing health services.

WINGS-4-FGS aims to generate evidence-based recommendations, enhance local capacity, and engage stakeholders and policymakers to integrate FGS care into African countries’ healthcare systems effectively. Success will lead to improved treatment guidelines and practices that will enable patients and healthcare workers to recognize, diagnose, and treat the disease before symptoms spread, as well as foster affordable local access to treatment and reduce associated stigma.

The transdisciplinary consortium brings together 11 renowned partners with expertise in tropical disease research, coming from 3 European (Germany, Switzerland and United Kingdom) and 6 African countries: Democratic Republic of Congo, Côte d’Ivoire and Malawi, where the clinical trials will be conducted, as well as Ghana, Madagascar and Rwanda.

WINGS-4-FGS will forge sustainable solutions for future generations of women and girls so they can feel empowered to manage their own reproductive health and overall well-being.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-GH-EDCTP3-2024-01-two-stage

See all projects funded under this call

Coordinator

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER
Net EU contribution
€ 885 169,11
Address
KEPPEL STREET
WC1E 7HT London
United Kingdom
Region
London Inner London — West Camden and City of London
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 885 169,11

Participants (7)

Partners (3)